阅读说明：本技术 抗病毒整理剂、抗病毒织物及其制备方法 (Antiviral finishing agent, antiviral fabric and preparation method thereof ) 是由 林玉平 林雪 孙卓然 王琍 李玲惠 于 2021-09-14 设计创作，主要内容包括：本发明涉及一种抗病毒整理剂,包括抗病毒物质和含水介质,所述抗病毒物质为含钼和/或钨的化合物,或者为钨钼氧酸盐。此外,还涉及由该抗病毒整理剂形成的织物以及该抗菌织物的制备方法。本发明的抗病毒织物能够有效抵抗常见致病细菌和病毒；抗菌率大于99.9％,抗病毒活性率大于99％；安全无毒,不改变细胞遗传特性、不致癌、不产生耐药性；高效持久,一次制作,可产生长期的抗病毒性和抗菌性。(The invention relates to an antiviral finishing agent, which comprises an antiviral substance and an aqueous medium, wherein the antiviral substance is a compound containing molybdenum and/or tungsten, or is tungsten molybdate. In addition, the fabric formed by the antiviral finishing agent and the preparation method of the antibacterial fabric are also related. The anti-virus fabric can effectively resist common pathogenic bacteria and viruses; the antibacterial rate is more than 99.9 percent, and the antiviral activity rate is more than 99 percent; safe and nontoxic, does not change the cell genetic characteristics, does not cause cancer, and does not generate drug resistance; high efficiency, long lasting effect, one-time production and long-term antiviral and antibacterial property.)

1. An antiviral finishing agent comprises an antiviral substance and an aqueous medium, and is characterized in that the antiviral substance is a molybdenum and/or tungsten-containing compound, and is selected from one or more of molybdenum and/or tungsten oxide, molybdenum and/or tungstate and molybdenum and/or tungsten-containing polyoxometallate.

2. The antiviral finish of claim 1, wherein the aqueous medium is water, an aqueous solution or a suspension.

3. The antiviral finish according to claim 1, wherein the weight proportion of the antiviral substance is from 0.01 to 20%, preferably from 0.05 to 2%, more preferably from 0.1 to 0.8%, based on the total weight of the antiviral finish.

4. The antiviral finish according to claim 1, further comprising a dispersant, wherein the dispersant is present in an amount of 0.005% to 0.05%, preferably 0.01% to 0.03%, based on the total weight of the antiviral finish.

5. The antiviral finish according to claim 1, further comprising a thickener, wherein the thickener is present in an amount of 0.05% to 0.9%, preferably 0.1% to 0.4%, based on the total weight of the antiviral finish.

6. The antiviral finish according to claim 1, further comprising an antifoaming agent, wherein the antifoaming agent is present in an amount of 0.05% to 1%, preferably 0.1% to 0.5%, based on the total weight of the antiviral finish.

7. The antiviral finish of claim 1, wherein the antiviral agent further comprises a bactericide, wherein the bactericide is present in an amount of 0.01% to 0.5%, preferably 0.01% to 0.05%, based on the total weight of the antiviral finish.

8. The antiviral finish according to any one of claims 1 to 7, wherein the antiviral substance is a molybdenum and/or tungsten containing compound supported on a carrier, said compound being selected from one or more of oxides, tungstates and polyoxometallates of molybdenum and/or tungsten, preferably said carrier is silica gel.

9. The antiviral finish according to claim 8, wherein the antiviral agent further comprises a binder, the binder being present in an amount of 0.05-5%, preferably 0.2-2.5%, based on the total weight of the antiviral finish.

10. An antiviral fabric, characterized in that the antiviral fabric is prepared by the following method: an antiviral finish according to any of claims 1 to 9 applied to a fabric and then dried to shape at a suitable temperature.

11. The antiviral fabric of claim 10, wherein the application method comprises spraying, brushing, dipping, padding.

12. The antiviral fabric of claim 10, wherein said fabric comprises a natural fiber fabric, a synthetic fiber fabric, and a blend fiber fabric and/or a union fiber fabric thereof.

13. A method for preparing an antiviral fabric, characterized in that an antiviral finish according to any one of claims 1 to 9 is applied to a fabric, and then dried and formed at a suitable temperature; preferably, the process is carried out after a conventional dyeing and finishing process.

14. The antiviral finish of claim 1, wherein said antiviral finish comprises elemental tungsten and elemental molybdenum as detected by X-ray fluorescence spectroscopy (XRF).

Technical Field

The invention belongs to the technical field of textiles, relates to a textile finishing agent, and particularly relates to an antiviral finishing agent. The invention also relates to a fabric formed by the antiviral finishing agent and a preparation method of the antiviral fabric.

Background

Scientific research has found that non-living surfaces can accumulate a large number of pathogenic bacteria and viruses, which are particularly dangerous for multiple drug resistant bacteria and viruses. These pathogenic bacteria and viruses can survive or survive on the surface of an object for several months, and if preventive sterilization measures are not taken, pathogens attached to the surface of the object become a persistent source of infection transmission.

In the case of fabrics, bacteriostatic and/or antibacterial functions are often imparted to the fabric by dyeing and finishing techniques in order to prevent the spread of diseases and to improve the healthy living standard. The core component of the textile finishing agent is the bacteriostatic agent.

The common antiviral and antibacterial agents include quaternary ammonium salt compound, quaternary phosphonium salt compound, azole compound and guanidine compound, chitosan, chitin, folium Artemisiae Argyi and Aloe, etc., and metal ions such as Ag⁺，Cd²⁺，Hg²⁺And Cu²⁺However, the common antiviral and antibacterial agents generally have the defects of insufficient antiviral and antibacterial properties, easy loss, short time-effect and the like, particularly the antiviral effect generally cannot meet the daily requirement, the stability is poor, even the color of the fabric is easy to change, the demand of the fabric for resisting viruses is increasingly large at present, but a fabric antiviral agent with good antiviral effect is lacked.

Disclosure of Invention

In order to further resist the pathogenic viruses and bacteria, the invention provides an antiviral finishing agent, the main raw material is tungsten molybdate, the antiviral effect is obvious, the antiviral finishing agent can be kept in a virus-free state for a long time only by once preparation, the frequent disinfection and cleaning are not needed, and the repeated consumption and the secondary environmental pollution are avoided.

In particular, the invention relates to the following:

the invention provides an antiviral finishing agent, which comprises an antiviral substance and an aqueous medium, wherein the antiviral substance is a compound containing molybdenum and/or tungsten, and is selected from one or more of oxides, tungstates and polyoxometallates containing molybdenum and/or tungsten.

The aqueous medium may be water, an aqueous solution or a suspension, among others.

Wherein the weight proportion of the antiviral substance is 0.01-20%, preferably 0.05-2%, more preferably 0.1-0.8%, based on the total weight of the antiviral finishing agent.

Wherein the antiviral finishing agent further comprises a dispersant, wherein the content of the dispersant is 0.005-0.05%, preferably 0.01-0.03%, based on the total weight of the antiviral finishing agent.

Wherein the antiviral finishing agent further comprises a thickening agent, and the content of the thickening agent is 0.05-0.9%, preferably 0.1-0.4%, based on the total weight of the antiviral finishing agent.

Wherein the anti-virus finishing agent further comprises an antifoaming agent, and the content of the antifoaming agent is 0.05% -1%, preferably 0.1% -0.5%, based on the total weight of the anti-virus finishing agent.

Wherein, the antiviral agent also comprises a bactericide, and the content of the bactericide is 0.01-0.5 percent, preferably 0.01-0.05 percent based on the total weight of the antiviral finishing agent.

According to any one of the antiviral finishing agents, the antiviral substance is a molybdenum and/or tungsten-containing compound loaded on a carrier, the compound is one or more than two of molybdenum and/or tungsten oxide, molybdenum and/or tungstate and molybdenum and/or tungsten-containing polyoxometallate, and preferably, the carrier is silica gel.

Wherein the antiviral agent further comprises a binder, and the content of the binder is 0.05-5%, preferably 0.2-2.5%, based on the total weight of the antiviral finishing agent.

The invention also provides an antiviral fabric, which is prepared by the following method: applying the antiviral finish according to any of the preceding claims to a fabric and then drying to shape at a suitable temperature.

Wherein the application method comprises spraying, brushing, dipping and padding.

Wherein the fabric comprises natural fiber fabric, synthetic fiber fabric, and blended fiber fabric and/or blended fiber fabric thereof.

The invention further provides a method for preparing an antiviral fabric, wherein the antiviral finishing agent is applied to the fabric, and then the fabric is dried and formed at a proper temperature; preferably, the process is carried out after a conventional dyeing and finishing process.

The anti-viral finish according to any of the preceding claims, wherein the anti-viral finish comprises the elements tungsten and molybdenum as detected by X-ray fluorescence spectroscopy (XRF).

Effects of the invention

The anti-virus finishing agent provided by the invention can rapidly inactivate viruses, kill and inhibit bacteria by destroying the DNA or RNA structure of the viruses in an embedded manner through tungsten molybdate and molybdate, and has an anti-virus activity rate of more than 99.9% and an antibacterial rate of more than 99.99%.

According to the antiviral finishing agent disclosed by the invention, when the molybdenum oxide solution is used as an aqueous medium, the prepared antiviral finishing agent can play a bactericidal role at the same time, and the antiviral and antibacterial effects can be achieved without adding other bactericides.

When the loaded tungsten molybdate antiviral powder is adopted, the antiviral finishing agent can increase the surface specific area of the effective components and reduce the content of the effective components, thereby reducing the cost.

The antiviral fabric is prepared by a post-finishing method, has no toxic or side effect, and effectively resists common pathogenic microorganisms and super bacteria; the product is safe and harmless, does not change the cell genetic characteristics, does not cause cancer, and does not generate drug resistance; the high efficiency and durability are realized, the one-time preparation is long-term effective, and the anti-virus effective period is the same as the service life of the base material; the application is wide, and the medical, civil, military and industrial fields are covered.

Detailed Description

The invention will be further illustrated with reference to specific embodiments. It should be understood that these embodiments are merely illustrative of the present invention and are not intended to limit the scope of the present invention. Further, it should be understood that various changes or modifications of the present invention may be made by those skilled in the art after reading the contents of the present invention, and those equivalents may fall within the scope of the present invention defined by the appended claims.

The invention provides an antiviral finishing agent, which comprises an antiviral substance and an aqueous medium and is characterized in that the antiviral substance is a molybdenum and/or tungsten-containing compound, and is selected from one or more of molybdenum and/or tungsten oxide, molybdenum and/or tungstate and molybdenum and/or tungsten-containing polyoxometallate.

The antiviral finishing agent according to the present invention, wherein the aqueous medium may be purified water, deionized water, an aqueous solution or a suspension.

In one embodiment, the aqueous medium is deionized water.

The antiviral finishing agent according to the present invention, wherein the antiviral substance is tungsten molybdate.

The tungsten molybdate has an antiviral effect as a member of polyoxometallates, which effectively kills bacteria, viruses and molds by virtue of the quadruple antimicrobial activity generated in situ. Firstly, forming acidified water molecules which can be permanently reserved on the surface of an object on the surface of the object through activity, thereby forming a weak acid environment with a lower pH value, effectively inhibiting the cell growth process, destroying a microbial phospholipid membrane and realizing protein denaturation; as the potential of the viral membrane decreases, no more effective energy is generated, causing membrane damage. The second activity, similar to the mechanism of photo-catalytic sterilization, can react with water on the surface of an object and in the air to generate active species such as active oxygen (superoxide anion) and hydroxyl radical to form free radicals. The active hydroxyl group is a strong oxidant, and is effective for nucleic acid, protein and bacteriaMetabolic enzymes have a decomposing and inactivating effect, resulting in the death of microorganisms. Third Activity, the presence of Mo on the surface of polyoxometallate coatings was detected using electron paramagnetic resonance spectrometer EPR⁵⁺The metal cations exceed the living range of various pathogenic microorganisms due to the low pH value, so that the living environment of the microorganisms is seriously damaged, the cell membrane permeability of the microorganisms is enhanced, and cell metabolic enzymes and the cell nucleus structure are damaged by the rapid penetration of the hydrogen ions and the metal cations, thereby killing the microorganisms. A fourth activity: polyoxometallate antiviral agents exhibit high antiviral activity. The high Zeta potential of the tungsten molybdate is an important factor for generating electrostatic action, and the energy of electrostatic combination is strong, so that the tungsten molybdate is stable. Therefore, the excellent antiviral activity can be generated. Can kill various pathogenic microorganisms including methicillin-resistant staphylococcus aureus MRSA and bacterial spores, and has the characteristics of high efficiency, rapidness, broad spectrum, durability, environmental protection and the like.

The antiviral finishing agent according to the present invention, wherein the weight ratio of the antiviral substance is 0.01 to 20% based on the total weight of the antiviral finishing agent. The weight ratio may further be, for example, 0.02 to 19.9%, 0.05 to 19.5%, 0.1 to 19%, 0.2 to 18%, 0.3 to 17%, 0.3 to 16%, 0.3 to 15%, 0.3 to 12%, 0.3 to 10%, 0.3 to 8%, 0.4 to 5%, 0.4 to 2%, 0.5 to 1%, 0.6 to 1%, 0.7 to 1%, 0.8 to 1%.

Preferably, the weight proportion of the antiviral substance is 0.1-10%; more preferably, the weight ratio of the antiviral substance is 0.3-1.5%.

In a particular embodiment, the weight proportion of the antiviral substance is 0.8%, based on the total weight of the antiviral finish.

The antiviral finishing agent according to the invention further comprises a dispersant.

As examples of the dispersant, BYK-180 (Bick, Germany), AKN-2280 (Qianzhito chemical Co., Ltd., Buddha), HLD-5 dispersant (silcona, Germany), MOK5676 dispersant (Merck, Germany) and the like, or a mixture of two or more thereof may be cited.

In a particular embodiment, the dispersant is selected from BYK-180 (Bick, Germany).

The antiviral finishing agent according to the present invention, wherein the weight ratio of the dispersant is 0.005% to 0.05%, for example, 0.007%, 0.01%, 0.015%, 0.02%, 0.025%, 0.03%, 0.035%, 0.4%, 0.045%, 0.05%, preferably 0.01% to 0.03%, based on the total weight of the antiviral finishing agent.

In a specific embodiment, the weight proportion of the dispersant is 0.015% based on the total weight of the antiviral finish.

The antiviral finishing agent according to the invention further comprises a thickening agent.

As examples of the thickener, BYK-420 (Bick, Germany), ZW707 water-based paint thickener (New Material, Kyowa, Guangzhou), CO-0065 thickener (New Material, Guangdong-Hai), and the like, or a mixture of two or more thereof can be given.

The antiviral finishing agent according to the present invention, wherein the content of the thickener is 0.05% to 0.9%, for example, 0.05%, 0.06%, 0.07%, 0.08%, 0.09%, 0.1%, 0.15%, 0.2%, 0.26%, 0.3%, 0.4%, 0.5%, 0.6%, 0.7%, 0.8%, 0.9%, preferably 0.1% to 0.4%, based on the total weight of the antiviral finishing agent.

In a particular embodiment, the weight proportion of the thickener is 0.3% based on the total weight of the antiviral finish.

The antiviral finishing agent according to the invention further comprises an antifoaming agent.

As examples of the antifoaming agent, BYK-093 (Bick, Germany), T-3001 (Hill. Foshozui chemical technology, TD-1330 (Tiande Fine chemical Co.), etc., or a mixture of two or more thereof may be mentioned.

In a specific embodiment, the antifoaming agent is selected from BYK-093 (Bick, Germany).

The anti-viral finishing agent according to the present invention, wherein the weight ratio of the defoaming agent is 0.05% to 1%, for example, 0.05%, 0.06%, 0.07%, 0.08%, 0.09%, 0.1%, 0.2%, 0.3%, 0.4%, 0.5%, 0.6%, 0.7%, 0.8%, 0.9%, 1%, preferably 0.1% to 0.5%, based on the total weight of the anti-viral finishing agent.

In a specific embodiment, the defoamer is present in a weight proportion of 0.2% based on the total weight of the antiviral finish.

The antiviral finishing agent according to the invention further comprises a bactericide.

In a particular embodiment, the biocide is selected from Polyhexamethylene Hydrochloride (PHMB).

The bactericide according to the present invention is the bactericide in the amount of 0.01% to 0.5%, for example, 0.01%, 0.02%, 0.03%, 0.05%, 0.07%, 0.08%, 0.09%, 0.1%, 0.16%, 0.2%, 0.28%, 0.3%, 0.4%, 0.5%, preferably 0.01% to 0.05%, based on the total weight of the antiviral finishing agent.

In a specific embodiment, the weight proportion of the biocide is 0.02%, based on the total weight of the antiviral finish.

In some embodiments of the present invention, the antiviral substance of the antiviral finish of the present invention is attached to the surface of the fiber in the form of a molecular lattice, and can withstand the shearing force of a general respiratory gas flow without an adhesive due to the attraction of van der waals force, and is not easily detached from the surface of the fiber.

The antiviral finishing agent according to the present invention is characterized in that the antiviral substance is one or more of oxides of molybdenum and/or tungsten, molybdenum and/or tungstates, and polyoxometallates containing molybdenum and/or tungsten, which are supported on a carrier.

Preferably, the carrier is silica gel.

In a specific embodiment, the supported molybdenum and/or tungsten-containing compound is a tungsten molybdate supported on a carrier.

The loaded tungsten-molybdenum oxysalt can be 10 wt% loaded tungsten-molybdenum oxysalt, 20 wt% loaded tungsten-molybdenum oxysalt, 30 wt% loaded tungsten-molybdenum oxysalt, 40 wt% loaded tungsten-molybdenum oxysalt, 50 wt% loaded tungsten-molybdenum oxysalt, 60 wt% loaded tungsten-molybdenum oxysalt, 70 wt% loaded tungsten-molybdenum oxysalt, 80 wt% loaded tungsten-molybdenum oxysalt or 90 wt% loaded tungsten-molybdenum oxysalt.

In a specific embodiment, the loaded tungsten molybdate may be 30 wt% loaded tungsten molybdate

In a specific embodiment, the loaded tungsten molybdate may be 50 wt% loaded tungsten molybdate

The antiviral finishing agent according to the invention further comprises a binder. The adhesive fixes the loaded tungsten-molybdenum-oxygen salt on the surface of the non-woven fabric fiber, so as to avoid falling off from the surface of the fiber.

As examples of the binder, acrylic emulsion, urethane emulsion, polyvinyl alcohol emulsion, and the like, or a mixture of two or more thereof may be cited.

In a particular embodiment, the binder is selected from acrylate emulsions.

The antibacterial finishing agent according to the invention is characterized in that the weight proportion of the binder is 0.05-5% based on the total weight of the antibacterial finishing agent. Preferably, the weight proportion of the binder is 0.1-4%; more preferably, the weight proportion of the binder is 0.2-2.5%; and, most preferably, the weight proportion of the binder is 0.5-1.5%.

In addition to the above, the antiviral finish according to the present invention optionally comprises various adjuvants or auxiliary ingredients well known in the art. Such adjuvants or auxiliary ingredients include, but are not limited to, dyes, pigments, softeners, cross-linking agents, leveling agents, brighteners, fixing agents, raising agents, refining agents, stabilizers, complexing agents, defoamers, smoothing agents, brighteners, soaping agents, resists, penetrants, deodorants, anti-uv agents, antistatic agents, and the like.

The amounts of these auxiliaries or auxiliary components are well known to those skilled in the art.

The invention also provides an antiviral fabric, which is characterized by being prepared by the following method: the antiviral finish of the present invention as described previously is applied to the fabric and then dried to shape at a suitable temperature.

The antiviral fabric according to the present invention as set forth above, wherein the application method includes, but is not limited to, spraying, brushing, dipping, padding, and the like. These application methods are well known to those skilled in the art.

Examples of the spray coating include: the antiviral finishing agent is diluted by water by a certain multiple, is uniformly sprayed on the surface of the fabric by a spray gun, and is shaped and dried. Advantageously, the dilution factor is 1 to 200, preferably 2 to 100, more preferably 5 to 50 and most preferably 10 to 20.

Examples of brushing include: the anti-viral finish of the present invention is adjusted to a suitable viscosity, uniformly brushed onto the fabric surface using a brush, and then set and dried.

Examples of impregnation include: diluting the anti-virus finishing agent by water by a certain multiple, soaking the fabric in the diluted anti-virus finishing agent by a certain ratio, controlling the bath ratio to be 1:10-40, controlling the bath temperature to be 40-95 ℃, fully soaking to enable the anti-virus finishing agent to fully contact the fabric, and then cooling to room temperature for spin-drying.

Examples of padding include: the fabric is made to pass through the diluent of the antiviral finishing agent, the bath ratio is controlled to be 1:10-40, the bath temperature is controlled to be 40-95 ℃, the rolling residue rate is 110-40%, and then the fabric is shaped and dried. If necessary, padding may be performed two or more times to achieve the desired antiviral agent binding capacity and antiviral properties.

The antiviral fabric according to the present invention, wherein the drying temperature is 20 to 110 ℃. Preferably, the drying temperature is 25-90 ℃; more preferably, the drying temperature is 30-80 ℃; and, most preferably, the drying temperature is 55-70 ℃.

In a specific embodiment, the drying temperature is 60 ℃.

The antiviral fabric according to the foregoing aspects of the invention, wherein the dry weight of the antiviral finish is 0.1 to 20% based on the dry weight of the antiviral fabric.

Preferably, the dry weight of the antiviral finish is 0.1-15%; more preferably, the dry weight of the antiviral finish is 0.3-5%; and, most preferably, the dry weight of the antiviral finish is from 0.5 to 1%.

In a specific embodiment, the dry weight of the antiviral finish is 0.5% based on the dry weight of the antiviral fabric.

The antiviral fabric according to the present invention, wherein the fabric includes, but is not limited to, natural fiber fabric, synthetic fiber fabric, and blended fiber fabric and/or blended fiber fabric thereof.

Examples of natural fibers include: cotton, wool, silk, hemp, etc.

Examples of synthetic fibers include: silk, acrylic, nylon, polyester, polypropylene, vinylon, polyethylene fibers, carbon fibers, and the like.

From a morphological point of view, the types of fabrics of the present invention include, but are not limited to, yarns, wool tops, woven fabrics, knitted fabrics, nonwoven fabrics, apertured films, and the like.

The antiviral fabric according to the present invention may be used as underwear and pants, sportswear, socks, shoe pads, gloves, neckerchief, hat, carpet, curtain, tablecloth, shower curtain, bedding, seat cushion, automotive upholstery fabric, mask, medical gauze, medical bandage, surgical gown, medical gown, hospital gown, air high efficiency filter, air primary filter cotton, automotive air cleaner, diaper, sanitary napkin, and the like.

The invention also provides a preparation method of the antiviral fabric, which is characterized in that the antiviral finishing agent is applied to the fabric, and then the fabric is dried and formed at a proper temperature.

The preparation method according to the invention is carried out after the conventional dyeing and finishing process.

Further, the invention also provides an antiviral fabric, wherein the fabric is obtained by the preparation method.

In yet another aspect, the present invention provides an antiviral fabric wherein the fabric comprises the elements molybdenum and/or tungsten as detected by X-ray fluorescence spectroscopy (e.g., shimadzu XRF-1800X-ray fluorescence spectroscopy).

In the present invention, any instrument capable of X-ray fluorescence spectroscopy can be used, and the detection can be carried out according to the manual of the specific instrument, the method described in the manual and/or the specification, and in the specific example, Shimadzu XRF-1800X-ray fluorescence spectrometer is used.

Has the advantages that:

the antiviral finishing agent provided by the invention has excellent antiviral effect, the antiviral activity rate of an antiviral layer detected by aiming at influenza A virus H1N1(A/PR/8/34) (host name: MDCK) is more than 99%, and the antiviral finishing agent has good antibacterial effect at the same time, and the bactericidal rate of the antiviral finishing agent for escherichia coli and staphylococcus aureus is more than 99.9%.

As for the antibacterial and antiviral stability of the antiviral finishing agent provided by the invention, tests show that the antiviral activity of the antiviral layer on influenza A virus H1N1 is not less than 2 years, the bactericidal effect on escherichia coli and staphylococcus aureus can be maintained for at least 2 years at room temperature, and the antiviral finishing agent has very good antibacterial and antiviral stability.

The antiviral finishing agent provided by the invention is non-toxic and harmless through toxicity tests, and can be used for finishing various textiles.

According to the antiviral finishing agent disclosed by the invention, when the molybdenum oxide solution is used as an aqueous medium, the prepared antiviral finishing agent can play a bactericidal role at the same time, and the antiviral and antibacterial effects can be achieved without adding other bactericides.

When the loaded tungsten molybdate antiviral powder is adopted, the antiviral finishing agent can increase the surface specific area of the effective components and reduce the content of the effective components, thereby reducing the cost.

The antiviral fabric is prepared by a post-finishing method, has no toxic or side effect, and effectively resists common pathogenic microorganisms and super bacteria; the product is safe and harmless, does not change the cell genetic characteristics, does not cause cancer, and does not generate drug resistance; the high efficiency and durability are realized, the one-time preparation is long-term effective, and the anti-virus effective period is the same as the service life of the base material; the application is wide, and the medical, civil, military and industrial fields are covered.

Examples

The present invention is described in further detail below with reference to specific examples.

Specific gravity of each component in each example

Example 1

Soaking the cotton gauze substrate of the pure textile in the antiviral finishing agent for 5 minutes, rolling after soaking, and drying the cotton gauze of the pure textile after soaking and rolling in a drying box at the temperature of 80 ℃ to obtain the antiviral cotton fabric. Wherein the antiviral finishing agent comprises the following components: 0.8 part of tungsten molybdate antiviral powder (self-produced by Anba biotechnology, Inc. of three rivers), 0.04 part of dispersant BYK180 (Bick, Germany), 0.3 part of thickener BYK420 (Bick, Germany) and 98.86 parts of 0.45 wt% molybdenum oxide solution.

Example 2

Soaking a polypropylene (PP) non-woven fabric substrate in an antiviral finishing agent for 10 minutes, rolling after soaking, and drying the soaked and rolled PP non-woven fabric in a drying oven at the temperature of 80 ℃ to obtain the antiviral non-woven fabric. Wherein the antiviral finishing agent comprises the following components: 0.6 part of tungsten molybdate antiviral powder (self-produced by Anba biotechnology, Sanhe), 0.03 part of dispersant BYK180 (Germany Bike), 0.25 part of thickener BYK420 (Germany Bike), 0.2 part of defoamer BYK093 (Germany Bike), 0.12 part of 20 wt% bactericide polyhexamethylene hydrochloride PHMB (beautiful chemical company, Foshan city), and 98.80 parts of deionized water.

Example 3

Soaking a Polyester (PET) non-woven fabric substrate in an antiviral finishing agent for 6 minutes, rolling after soaking, and drying the soaked and rolled Polyester (PET) non-woven fabric in a drying oven at the temperature of 80 ℃ to obtain the antiviral non-woven fabric. Wherein the antiviral finishing agent comprises the following components: 0.5 part of tungsten molybdate antiviral powder (self-produced by Anba biotechnology, Sanhe), 0.03 part of dispersant BYK180 (Germany Bike), 0.2 part of thickener BYK420 (Germany Bike), 0.2 part of defoamer BYK093 (Germany Bike), 0.15 part of 20 wt% bactericide polyhexamethylene hydrochloride PHMB (beautiful chemical company, Foshan city), and 98.92 parts of deionized water.

Example 4

Soaking a polypropylene (PP) non-woven fabric substrate in an antiviral finishing agent prepared by 30 wt% of load tungsten molybdate for 5 minutes, rolling after soaking, and drying the soaked and rolled PP non-woven fabric in a drying oven at 80 ℃ to obtain the antiviral non-woven fabric. Wherein the antiviral finishing agent comprises the following components: 0.3 part by weight of 30 wt% tungsten-molybdenum-oxide-loaded antiviral powder (self-produced by Anba biotechnology, Inc. in Sanhe City), 0.02 part by weight of dispersant BYK180 (Bick, Germany), 0.4 part by weight of thickener BYK420 (Bick, Germany), 0.3 part by weight of defoamer BYK093 (Bick, Germany), 0.12 part by weight of 20 wt% bactericide polyhexamethylene hydrochloride PHMB (Lizechenyield chemical company), 0.5 part by weight of acrylate 2383A (Fushan Bady Fukui-Shi corporation) and 98.36 parts by weight of deionized water.

Wherein, 30 wt% of the loaded tungsten molybdate can be prepared according to the following method: adding 30 parts by weight of POM tungsten molybdate powder into a proper amount of deionized water, stirring uniformly, adding 70 parts by weight of No. 3 silica gel (Qingdao Xin Yonglai silica gel company), stirring uniformly to fully mix the tungsten molybdate powder and the silica gel, completely immersing the mixture in the liquid, standing for 24 hours, and drying in a drying oven of 150 ℃.

Example 5

Soaking a polypropylene (PP) non-woven fabric substrate in an antiviral finishing agent prepared by 50 wt% of load tungsten molybdate oxide for 5 minutes, rolling after soaking, and drying the soaked and rolled PP non-woven fabric in a drying oven at 80 ℃ to obtain the antiviral non-woven fabric. Wherein the antiviral finishing agent comprises the following components: 0.1 part by weight of 50 wt% loaded tungsten molybdate antiviral powder (self-produced by Anba biotechnology, Inc. in Sanhe City), 0.01 part by weight of dispersant BYK180 (Bick Germany), 0.3 part by weight of thickener BYK420 (Bick Germany), 0.15 part by weight of defoamer BYK093 (Bick Germany), 0.12 part by weight of 20 wt% bactericide polyhexamethylene hydrochloride PHMB (Lizecheng chemical Co., Ltd., Fushan City), 0.5 part by weight of acrylate 2383A (Fushan Bade Fukui Co., Ltd.), and 98.82 parts by weight of deionized water.

Wherein, the 50 wt% load tungsten molybdate can be prepared according to the following method: adding 50 parts by weight of POM tungsten molybdate powder into a proper amount of deionized water, stirring uniformly, adding 50 parts by weight of No. 3 silica gel (Qingdao Xin Yonglai silica gel company), stirring uniformly to fully mix the tungsten molybdate powder and the silica gel, completely immersing the mixture in the liquid, standing for 24 hours, and drying in a drying oven of 150 ℃.

Test examples

To verify the performance of the antiviral finish of the present invention, experimental examples were individually subjected to performance tests on examples 1 to 5.

Test example 1 antibacterial and antiviral test conducted for example 1

The anti-bacterial performance test of the anti-viral non-woven fabric prepared in the example 1 is carried out according to the antibacterial activity determination absorption method of the international standard ISO20743-2013 textile/textile product, and the result shows that the antibacterial rate of the anti-viral non-woven fabric to escherichia coli and staphylococcus aureus is more than 99.9%.

The antiviral nonwoven fabric prepared in example 1 was subjected to antiviral performance test by the Guangdong province microbiological analysis and detection center. The test measures the antiviral activity of the antiviral layer against influenza A virus H1N1(A/PR/8/34) (host name: MDCK) according to ISO 18184:2019 (E). The results showed that the antiviral activity value of the antiviral layer was 3.03 and the antiviral activity rate was 99.91%.

Test example 2 antibacterial and antiviral test conducted for example 2

The antiviral nonwoven fabric prepared in example 2 was subjected to antibacterial performance test by Guangdong institute for microorganisms, Inc. The test measures the antibacterial performance and the bactericidal rate of the antiviral layer against escherichia coli ATCC25922 and staphylococcus aureus ATCC6538 according to the antibacterial activity assay (absorption method) of ISO 20743:2013 textile-laid products. The result shows that the antibacterial activity value of the antiviral layer against escherichia coli is greater than 7.2, and the sterilization rate is greater than 99.9%; the antibacterial activity value of the antibacterial agent against staphylococcus aureus is greater than 6.9, and the sterilization rate is greater than 99.9%. The antiviral layer of the present invention has a strong antibacterial effect.

The antiviral nonwoven fabric prepared in example 2 was subjected to antiviral performance test by the Guangdong province microbiological analysis and detection center. The test measures the antiviral activity of the antiviral layer against influenza A virus H1N1(A/PR/8/34) (host name: MDCK) according to ISO 18184:2019 (E). The results showed that the antiviral activity value of the antiviral layer was 2.09, and the antiviral activity rate was 99.19%.

Test example 3 antibacterial, antiviral and toxicity tests carried out in connection with example 3

The antimicrobial property test of the antiviral nonwoven fabric prepared in experimental example 3 was carried out by entrusted Guangzhou microbial research institute, Inc. according to the antimicrobial activity measurement absorption method of the textile/textile product according to the international standard ISO20743-2013, and the results show that the antimicrobial activity values of the antiviral nonwoven fabric on Escherichia coli and Staphylococcus aureus are 7.5 and 6.6 respectively, and the antimicrobial rates are both more than 99.99%.

The antiviral nonwoven fabric prepared in example 3 was subjected to antiviral performance test by the Guangdong province microbiological analysis and detection center. The test measures the antiviral activity of the antiviral layer against influenza A virus H1N1(A/PR/8/34) (host name: MDCK) according to ISO 18184:2019 (E). The results showed that the antiviral activity value of the antiviral layer was 2.03 and the antiviral activity rate was 99.06%.

The antiviral nonwoven fabric prepared in example 3 was subjected to toxicity test by Guangzhou microbial research institute, Inc. The test was conducted according to disinfection specifications (2002 edition) 2.3.1, 2.3.8.4, 2.3.3.3.3, respectively, to evaluate the irritation of the sample by acute oral toxicity test, mutagenesis test (mouse bone marrow polycystic erythrocyte micronucleus test), and multiple complete skin irritation tests.

The results show that the antiviral agent is practically non-toxic according to the evaluation provisions of the acute oral toxicity test in the Disinfection Specification (2002 edition); the antiviral agent has no micronucleus-causing effect on NIH mice according to the evaluation regulation of 2.3.8.4 mice marrow polycystic erythrocyte micronucleus test in disinfection technical Specification (2002 edition); the skin irritation intensity was graded according to the skin irritation test of "Disinfection Specification" (2002 edition) 2.3.3, and was non-irritating.

Test example 4 antimicrobial property and antimicrobial stability test for example 4

The anti-virus non-woven fabric prepared in the experimental example 4 is subjected to an antibacterial performance experiment according to an antibacterial activity determination absorption method of an international standard ISO20743-2013 textile/textile product, and the result shows that the antibacterial rates of the anti-virus non-woven fabric on escherichia coli and staphylococcus aureus are both more than 99.9%.

The antiviral nonwoven fabric prepared in example 4 was subjected to an antibacterial stability test by Guangzhou microbial research institute, Inc. The test is based on the antibacterial activity determination of ISO20743 and 2013 textile, and an absorption method; the antibacterial stability of the antiviral agents was tested against E.coli (8099) and Staphylococcus aureus (ATCC 6538). And (3) placing the sample in an environment with the relative humidity of more than 75% and the temperature of 37-40 ℃ for 3 months, and then carrying out antibacterial detection. The detection result shows that the antibacterial activity value of the antiviral non-woven fabric against escherichia coli is greater than 7.4, and the sterilization rate is greater than 99.9%; the antibacterial activity value of the antibacterial agent against staphylococcus aureus is greater than 6.9, and the sterilization rate is greater than 99.9%. The bactericidal effect on escherichia coli and staphylococcus aureus reaches the standard value specified in WS/T650-2019 'evaluation method for antibacterial and bacteriostatic effects', and the bactericidal effect of the product on escherichia coli and staphylococcus aureus can be maintained for at least 2 years at room temperature.

Test example 5 antibacterial and antiviral stability tests carried out for example 5

The anti-virus non-woven fabric prepared in the experimental example 5 is subjected to an antibacterial performance experiment according to an antibacterial activity determination absorption method of an international standard ISO20743-2013 textile/textile product, and the result shows that the antibacterial rates of the anti-virus non-woven fabric on escherichia coli and staphylococcus aureus are both more than 99.99%.

The antiviral nonwoven fabric prepared in example 5 was subjected to antiviral stability test by Guangzhou microbial research institute, Inc. The test measures the antiviral activity of the antiviral layer against influenza A virus H1N1(A/PR/8/34) (host name: MDCK) according to ISO 18184:2019 (E).

The result shows that the antiviral activity value of the antiviral non-woven fabric is 1.78 and the antiviral activity rate reaches 96.11 after 3 months in the environment with the relative humidity of more than 75% and the temperature of 37-40 ℃. According to the national standard GB15979-2002 hygienic standard of disposable sanitary products or the group standard TCIAA014-2021 mask antiviral performance and evaluation thereof, the antiviral activity of the antiviral layer on influenza A virus H1N1 is not less than 2 years.

The above description is only a preferred embodiment of the present invention and is not intended to limit the present invention, and various modifications and changes may be made by those skilled in the art. Any modification, equivalent replacement, or improvement made within the spirit and principle of the present invention should be included in the protection scope of the present invention.